AVITA Medical, Inc. (RCEL) FY2025 10-K Annual Report
AVITA Medical, Inc. (RCEL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
AVITA Medical, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model: Multi-product acute wound care platform focused on autologous cell harvesting technology RECELL plus complementary wound matrices
- • New products: Commercial launch of Cohealyx collagen dermal matrix (Apr 2025) and FDA approval/commercial rollout of RECELL GO mini for smaller wounds (Dec 2024)
- • Strategic shift: Expansion from burn centers into trauma and surgical wound markets with broadened RECELL indications for full-thickness skin defects
- • Quantitative metric: Employee count approx. 226 as of Dec 31, 2025; multiple multi-year distribution and manufacturing agreements for PermeaDerm and Cohealyx
- • Noteworthy fact: CMS New Technology Add-On Payment (NTAP) approval effective Oct 1, 2025 for RECELL in inpatient non-thermal full-thickness skin defects
Management Discussion & Analysis
- • Revenue $71.6M in 2025, up 11% YoY from $64.3M in 2024, driven by deeper penetration and new accounts
- • Gross margin 82.1% in 2025 vs 85.8% in 2024; decrease due to product mix and higher inventory reserve
- • Best segment: RECELL products gross margin 84.3%; Cohealyx and PermeaDerm at 50% and 60% ASP respectively reducing overall margin
- • Operating expenses $101.4M in 2025, down 9% YoY from $111.8M; sales & marketing down 9% to $53.1M, G&A down 18% to $27.3M; R&D up 2% to $20.8M
- • Net loss $48.6M in 2025, improved 21% vs $61.8M loss in 2024
- • Cash and equivalents $10.2M, marketable securities $7.9M at end 2025; new $60M credit facility closed Jan 2026 with $50M funded, refinancing prior debt
- • Key risk: ongoing debt covenants require TTM revenue minimums ($68.5M Q1 2026, $73M full year), substantial doubt about going concern due to recurring losses and debt obligations
- • Positive outlook supported by FDA NTAP reimbursement for RECELL (effective Oct 2025-Sept 2026) and CE Mark for RECELL GO in EU
Risk Factors
- • Regulatory risk: dependency on FDA PMA for RECELL, risk of modification/suspension/revocation impacting U.S. operations
- • Macroeconomic risk: $60M five-year senior secured credit facility with Perceptive, subject to net revenue covenants and rising interest rate exposure
- • Supply chain risk: single-sourcing some critical material components since 2023, risking production delays and cost increases
- • Competitive risk: rivals with greater financial resources could develop products rendering RECELL obsolete
- • Financial risk: cumulative deficit $408.4M, net loss $48.6M in 2025, with continuing operating losses and cash flow insufficiency to service debt
AVITA Medical, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$72M
▲ +11.5% YoY
Net Income
-$49M
▲ +21.4% YoY
Gross Margin
82.1%
▼ -371bp YoY
Operating Margin
-59.4%
▲ +2868bp YoY
Net Margin
-67.8%
▲ +2841bp YoY
ROE
291.8%
▲ +166645bp YoY
Total Assets
$56M
▼ -29.3% YoY
EPS (Diluted)
$-1.74
▲ +27.2% YoY
Operating Cash Flow
-$31M
▲ +36.3% YoY
Source: XBRL data from AVITA Medical, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on AVITA Medical, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.